EUVIMEDEUVIMED entdecken
Crossref

Metal–Organic Framework and 5-Fluorouracil Co-Encapsulated Hyaluronic Acid/Carboxymethyl Chitosan Hydrogels for Synergistic Chemotherapy and Enhanced Chemodynamic Therapy

Wenqian Bai, Miaomiao Li, Junyao Li iD, Wenrong Cai, Yong Kong iD, Haiying Chen

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Wenqian Bai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Advanced Materials and Technology, School of Petrochemical Engineering, Changzhou University, Changzhou 213164, China. Hauptthemen laut MEDLINE: Hyaluronic Acid, Chitosan, Fluorouracil, Hydrogels. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A vitamin K3 (VK3)-loaded metal-organic framework (Cu/ZIF-8/VK3) was synthesized by a one-pot method. After the coencapsulation of Cu/ZIF-8/VK3 and 5-fluorouracil (5-FU) in the hyaluronate acid (HA)/carboxymethyl chitosan (CMCS) hydrogels formed via an amidation reaction, a drug-controlled release system (Cu/ZIF-8/VK3/5-FU/HA/CMCS) was obtained. In the weakly acidic media, the amide bonds in the HA/CMCS hydrogels are prone to be hydrolyzed, resulting in the release of 5-FU and Cu/ZIF-8/VK3; and the Cu/ZIF-8/VK3 is further degraded in the acidic environment, leading to the release of VK3 and Cu2+. The released Cu2+ can be reduced by glutathione (GSH) to Cu+, which can react with intracellular H2O2 to produce cytotoxic hydroxyl radicals (·OH) for chemodynamic therapy (CDT). On the other hand, H2O2 can be replenished through the redox cycling of VK3 in the presence of NAD(P)H: quinone oxidoreductase-1 (NQO1), generating stable ·OH for enhanced CDT. Cytotoxicity assay demonstrates that the developed drug-controlled release system has excellent biocompatibility, which can effectively inhibit the growth of mouse breast tumor cells 4T1 due to the synergistic chemotherapy and enhanced CDT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidChitosanFluorouracilHydrogelsAnimalsMiceFemaleCell Line, TumorHumansCopperDrug CarriersDrug SynergismDrug LiberationGlutathioneDelayed-Action Preparations

Stichwörter der Autor:innen

carboxymethyl chitosanhyaluronic acidmetal−organic frameworksynergistic therapyvitamin K3

Substanzen

Hyaluronic AcidChitosanFluorouracilHydrogelscarboxymethyl-chitosanCopperDrug CarriersGlutathioneDelayed-Action Preparations

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Advanced Materials and Technology, School of Petrochemical Engineering, Changzhou University, Changzhou 213164, China.
  • Department of Pharmacy, Changzhou No.3 People's Hospital, Changzhou 213001, China.

ORCID-Profile: Junyao Li, Yong Kong

Förderung

  • Graduate Research and Innovation Projects of Jiangsu Province
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Bai, W., Li, M., Li, J., Cai, W., Kong, Y., & Chen, H. (2026). Metal–Organic Framework and 5-Fluorouracil Co-Encapsulated Hyaluronic Acid/Carboxymethyl Chitosan Hydrogels for Synergistic Chemotherapy and Enhanced Chemodynamic Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01519

Vancouver

Bai W, Li M, Li J, Cai W, Kong Y, Chen H. Metal–Organic Framework and 5-Fluorouracil Co-Encapsulated Hyaluronic Acid/Carboxymethyl Chitosan Hydrogels for Synergistic Chemotherapy and Enhanced Chemodynamic Therapy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01519

BibTeX
@article{Bai2026,
  author = {Bai, Wenqian and Li, Miaomiao and Li, Junyao and Cai, Wenrong and Kong, Yong and Chen, Haiying},
  title = {Metal–Organic Framework and 5-Fluorouracil Co-Encapsulated Hyaluronic Acid/Carboxymethyl Chitosan Hydrogels for Synergistic Chemotherapy and Enhanced Chemodynamic Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01519}
}
Kostenlos starten →